Dr. Melissa ZHANG has over 14 years of experience in venture capital investment, start-up and public company operations, and biomedical research in the life sciences industry in China. She also has working knowledge in company strategy, reorganization, M&A, IPO preparation, and corporate compliance.

Dr. Zhang is primarily responsible for deal sourcing, due diligence, structuring, and portfolio management for early stage bio-pharmaceutical companies to growth stage medical device companies. Prior to Cenova, Dr. Zhang was the Board Secretary and Senior Director of the Executive Office at Shanghai Genomics, a life science company listed on the Tokyo Stock Exchange.

Dr. Zhang received her M.D. from Fudan Medical School.

Mr. Frank FENG joined Cenova in 2017, serving as the Chief Financial Officer of the firm. He has extensive experiences in domestic and overseas public listing, company restructuring, and mergers and acquisitions. Prior to Cenova, Mr. FENG was the Chief Financial Officer of Suzhou Haowu and Ku6 Media (NASDAQ:KUTV), the Vice President of Finance at Taomee Holdings Ltd. (NASDAQ:TAOM) and the Director of Finance at Renesola Ltd. (NYSE: SOL). He was a financial auditor at Deloitte, PriceWaterhouseCoopers and KPMG for over 12 years. Mr. FENG became a member of the Chinese Institute of Certified Public Accountant in 1999 and received his Bachelor's Degree in Industrial Foreign Trade from Shanghai Jiaotong University in 1996.

Ms. Stella KWEK joined Cenova in 2017 and is responsible for Investor Relations, Fund Raising and Cross-Border Investments. She brings more than 20 years of combined investment, portfolio management and healthcare operations experience, having invested in life science companies in the pharmaceuticals, medical devices and diagnostics sectors in Asia, Europe and United States.

Ms. Kwek began her investment career more than ten years ago at the Life Sciences Investment team at Temasek Holdings, where she was responsible for investments, portfolio management and divestments. In 2013, she joined Pavilion Capital, a fully owned subsidiary of Temasek, to initiate their healthcare funds investment program and their life-sciences co-direct investments. She was formerly a Managing Director at Ally Bridge Group, responsible for investor relations, deal execution and specialty pharma. Earlier in her career, Ms. Kwek worked in various operating roles in the pharmaceutical and healthcare industry where she was responsible for commercialization, retail operations, advertising and promotions.

Ms. Kwek received her education in Singapore and the United Kingdom. She is a Sloan Fellow from London Business School, and holds a Masters in Applied Finance from the Singapore Management University, and a Bachelor of Accounting and Finance from the University of London. She is a registered pharmacist in Singapore.

Dr. Haohao ZHANG joined Cenova in 2012 and is primarily responsible for deal execution, portfolio management and divestments in biopharmaceuticals, medical devices and healthcare services companies. She has extensive experiences in RMB off-shore investments and has led the investments in ASLAN Pharmaceuticals (TWSE: 6497), Optomed, VIVACE Therapeutics and Lumo BodyTech.  

Prior to Cenova, Dr. Zhang was the Executive Scientific Assistant to the CEO of Shanghai Biomabs Pharmaceutical Co. Ltd., one of the leading antibody drug companies in China. At Biomabs, she coordinated the company's efforts in scientific due diligence, clinical development, regulatory compliance, and public relations.

Dr. Zhang received her Ph.D. in Cancer Pharmacology from the Shanghai Institute of Materia Medica, Chinese Academy of Sciences and her M.D. with honors from the Medical School of Jinan University, Guangzhou.

Ms. Rui JIN joined Cenova in 2010 with over 12 years of combined life-science investment and biomedical research experience.  She is primarily responsible for deal screening, due diligence, deal structuring and portfolio management. Previously, Ms. Jin played a key role in fund management, investor relations and internal risk control for Cenova's existing RMB funds. Prior to Cenova, she was the Manager of Drug Registry and Business Development at Shanghai Genomics, a life science company listed on the Tokyo Stock Exchange.

Ms. Jin holds a Masters in Molecular Biology from Shanghai Normal University.

Mr. Phaniah WANG joined Cenova’s investment team in 2015. He has more than ten years of experience in mergers and acquisitions and public listings for healthcare services, biotechnology, pharmaceuticals, chemicals, and large manufacturing companies. Prior to Cenova, he was a Senior Manager at PwC Shanghai and Hong Kong, providing mergers and acquisitions advisory services for private equity firms, multi-national companies and Chinese state-owned enterprises. His clients included Sequoia, TPG, CVC, Medtronic, Warburg Pincus, China Investment Corporation, FountainVest and Zhangjiang Venture Capital Group. Prior to PwC, Phaniah was a Financial Manager at Ernst & Young (Shanghai), where he led a 60-member team to provide assurance services for A and H-share listed companies.

Phaniah is a CICPA, and he graduated from Zhejiang University with a Bachelor's degree in Management.

Mr. Xiaoyin SHEN joined Cenova in 2017 with nearly six years of experience in healthcare investment. Prior to Cenova, he worked at China Everbright Limited Healthcare Fund I & II, Dalian Yifang Group and Simon Murray Capital and invested in bio-pharmaceuticals, consumer health, diagnostics and healthcare services.  Some of the investments that he has made included BGI (SZ: 300676), Betta Pharma (SZ: 300558), Etong Healthcare, Ambrx, Amcare, Beijing Jingdu Children’s Hospital and Xiuzheng Pharmaceutical Group. Mr. Shen was previously a senior associate at the Corporate Finance division of PwC, providing financial advisory services for Chinese outbound investments.

Mr. Shen graduated with a B.A. and M.A. in Economics from Renmin University of China and University of Connecticut respectively. He was also the co-author and translator of a book, “Fair Trade for All”.

Ms. Emily YANG joined Cenova in 2018 and is primary responsible for financial due diligence, financial modelling and valuation analysis.

Prior to Cenova, Ms. YANG spent 5 years at Duff & Phelps, a global valuation and corporate finance advisory. In this role, she provided financial advisory analysis for mergers and acquisitions, cross-border joint ventures, financial reporting and tax restructuring across various industries including life science companies. Ms. YANG had also worked at a risk consulting firm and PwC providing risk management and audit services under PRC, IFRS and US GAAP.

Ms. Yang is a CFA charter holder and holds the ACCA qualification. She graduated with a Master in Investment Management from Cass Business School, and a Bachelor in International Accounting from Shanghai University of Finance and Economics.

Ms. Yang ZHOU joined Cenova in 2017, and is primary responsible for due diligence, research and analysis, and investor relations support. Prior to Cenova, Ms. Zhou was an Associate at the life-science practice of L.E.K. Consulting, one of the leading global management consulting firms. She has worked on strategic planning, business growth, and due diligence projects for overseas and domestic healthcare companies and private equity firms. Some of her past projects included designing the China business growth strategy for a major global in-vitro diagnostics manufacturer, the healthcare investment strategy for a Chinese public listed company and formulating the pricing strategy for an innovative oncology drug.

Ms. Zhou graduated from the University of Southern California with a Bachelor of Science in Business Administration.

Ms. Yiying LI has over 30 years of experience in financial management and auditing, particularly in corporate finance, venture capital and private equity. Her domain knowledge includes Chinese GAAP and China’s tax and corporate law. Prior to Cenova, Ms. LI was in charge of investments and portfolio management at Shanghai International Growth Investment Ltd., an investment company listed on the Hong Kong Stock Exchange.

Ms. LI holds a Bachelor in Accounting from the Shanghai University of Finance and Economics. She was also an Associate Professor at Shanghai Lixin University of Commerce and has written many textbooks on finance and accounting.

Ms. Mandy ZHU joined Cenova in 2011.  She has rich experience in fund operation management and government affairs. Mandy's work includes fund architecture management, communication with custodian banks, preparation of financial and custody reports, compliance audit, internal audit and fund compliance reports.

Ms. Zhu has taken part in the establishment of several funds in Cenova. She is usually responsible for communication with the administration for industry and commerce/taxation/commerce commission and other government affairs, as well as capital operation management, etc.

Ms. ZHU graduated from Keele University and got a master of management degree. 

Ms. Li ZHOU joined Cenova in 2016 and is responsible for investor relations. Prior to Cenova, she was a placement agent with Diamond Dragon Advisors for six years. She started her financial career at ICBC as a credit officer and subsequently joined the team at Citi Asia Private Equity Program to review Asia based private equity managers.    

Ms. Zhou received a Bachelor in Law from Shanghai International Studies University.

Ms. Lu CHEN joined Cenova in 2017 and is primarily responsible for portfolio management and financial due diligence. Prior to Cenova, she worked at Ping An Group and Evergrande Group in financial and operating analysis, strategy and investor relations. Previously, Ms. CHEN was a Senior Associate at KPMG Shanghai and PwC New York, providing assurance services to various industries including pharmaceuticals, medical equipment, real estate investment trust (“REIT”s) and asset management companies.   

Ms. CHEN holds a Masters in Accounting (Transaction Services) from Wake Forest University and a Bachelor in Economics from Shanghai International Studies University. She is an AICPA and CMA.

Ms. Wen YUAN joined Cenova in 2016 with over 10 years administrative and operating experience in financial services. Ms. Wen YUAN is the treasury manager for USD Fund. She is also responsible for archive management for all funds. Prior to joining Cenova, Ms. Wen Yuan worked as an Executive Secretary at CITIC Capital and as an Administrative Assistant in Morgan Stanley.

Ms. Yuan has a B.A. in Broadcasting and Television and a B.A. in International Economics and Trade from Shanghai University.

Ms. Kelly LI joined Cenova in 2017 as an Office Manager to provide administrative support to the investment team. Previously, she was the Office Manager at Duff and Phelps and has more than ten years of administration experiences in financial and consultancy firms. She is well versed in various aspects of office administration, travel planning, events management and budgetary control. 

Ms. Li graduated with a Bachelor in Hospitality Management from East China Normal University.